Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase IIa, Multi-center, Double-blind, Placebo-controlled Study to Assess the Safety, Feasibility, Tolerability, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's Disease

Trial Profile

A Randomized Phase IIa, Multi-center, Double-blind, Placebo-controlled Study to Assess the Safety, Feasibility, Tolerability, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's Disease

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Montelukast (Primary)
  • Indications Alzheimer's disease
  • Focus Proof of concept; Registrational; Therapeutic Use
  • Acronyms BUENA
  • Sponsors IntelGenx Corp.
  • Most Recent Events

    • 01 Aug 2023 According to an IntelGenx Technologies media release, the company looking forward to completing the BUENA trial in the first quarter of 2024 and to reporting initial trial results the following quarter.
    • 01 Aug 2023 Planned number of patients changed from 70 to 54.
    • 01 Aug 2023 According to an IntelGenx Technologies media release, the enrollment for this study has been completed. The Company successfully enrolled 52 patients in the study, 18 fewer than initially planned. As the COVID-19 pandemic effectively halted recruitment for approximately 18 months, followed by imposed post-pandemic restrictions from hospitals, the company's rationale behind decreasing study enrollment was to avoid any further delay in achieving the program's goal.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top